Docetaxel, an antitumor drug of taxane compounds, can destroy the mitosis of tumor cells by enhancing tubulin polymerization and inhibiting tubulin depolymerization, thereby inhibiting the division and proliferation of tumor cells, and also reducing the serum PSA and VEGF levels of patients. This evidence concerns the gene KLK3 and neoplasm.